Where does stocks-llm's data on ANAB come from?

Fundamentals and prices come from Finnhub, as of 2026-07-10; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

← stocks-llm Find companies like ANAB →

ANAPTYSBIO INC (ANAB)

Health Care · Clinical-stage immunology biotechnology / royalty-stage drug development · NASDAQ

AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own clinical-stage pipeline for autoimmune and inflammatory diseases.

View SEC filings Website Yahoo Finance Find companies like ANAB → Ask about ANAB →

What ANAPTYSBIO INC does

AnaptysBio is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. Prior to a separation completed in April 2026, the company held a diversified pipeline including rosnilimab (for rheumatoid arthritis), ANB033 (for celiac disease and eosinophilic esophagitis), and ANB101 (BDCA2 modulator). Following the separation, the company now focuses on managing financial collaborations with GSK (for the approved immuno-oncology drug Jemperli/dostarlimab) and Vanda Pharmaceuticals (for imsidolimab), generating revenue primarily through milestone payments and royalties.

Themes: ["Immunology therapeutics","Autoimmune and inflammatory disease treatment","PD-1 antagonists / immuno-oncology","Royalty-based collaboration models","Rheumatoid arthritis","Endometrial cancer","Psoriasis","Clinical-stage development"]

Fundamentals

Price$66.59 as of 2026-07-09 close
Market cap$1.9B as of 2026-07-10
1-year return+288.1% as of 2026-07-09 close
Net margin-11.5% as of 2026-07-10
ROE-13.1% as of 2026-07-10
Debt / equity20.69 as of 2026-07-10
Revenue growth (YoY)+107.7% as of 2026-07-10
Revenue CAGR (3y)+183.6% SEC XBRL
Beta0.81 as of 2026-07-10

Ask why ANAB looks like this →

Key risks (from latest filing)

["Product candidates in development may fail or experience delays that adversely affect commercial viability; clinical trial results may not be representative of future trial outcomes.","The company has limited operating revenue, a history of operational losses, and no products approved for commercial sale; additional capital will be required to finance operations and complete development programs.","Dependence on GSK collaboration for Jemperli revenue and milestone recognition; loss or failure of this collaboration could materially adversely affect the business."]

See ANAB's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.